MP-RM-1
Based on 1 Customer Validation
MP-RM-1 is an antibody-based, non-competitive ErbB-3 inhibitor with a Kd value of 32.7 nM. MP-RM-1 inhibits both ligand-dependent and ligand-independent ErbB-3 activation, blocks ErbB-2/ErbB-3 heterodimerization, induces ErbB-3 internalization and degradation, and suppresses the phosphorylation of downstream Akt. MP-RM-1 exerts its antagonistic effect through a non-competitive mechanism. MP-RM-1 inhibits tumor growth in melanoma and prostate cancer xenograft models in nude mice and reduces the proliferative activity of tumor cells.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 96.29%
- Masse moléculaire:147.86 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform EGFR
More
Activité biologique
Human IgG1 kappa
Human
|
ErbB3 32.7 nM (Kd) |
MP-RM-1 (0.01-10 μg/mL; 15-120 min) inhibits NRG-1β-dependent phosphorylation of ErbB-3 and Akt in a dose- and time-dependent manner in breast cancer cells MDA-MB-435 and melanoma cells IR-8[1].
MP-RM-1 (10 μg/mL) significantly inhibits the colony-forming ability of IR-8 melanoma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MP-RM-1 (20 mg/kg; i.p.; twice weekly) significantly inhibits the growth of DU-145 prostate cancer xenografts in nude mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD-1 nu/nu (7-weeks old, melanoma xenograft via subcutaneous injection of IR-8 cells)[1]
-
Dosage:20 mg/kg (tumor growth delay); 20 mg/kg (tissue analysis)
-
Administration:i.p.; twice weekly (tumor growth delay); i.p.; single injection (tissue analysis)
-
Result:Caused significant tumor growth delay over 8 weeks.
Reduced ErbB-3 expression and Akt phosphorylation significantly compared to controls.
Decreased Ki-67 staining index to 35.8 vs 57.9 in controls (P = 0.048).
Decreased mitotic index to 6.6 vs 9.5 in controls (P = 0.017).
-
Animal Model:CD-1 nu/nu (7-weeks old, prostate cancer xenograft via subcutaneous injection of DU-145 cells)[1]
-
Dosage:20 mg/kg
-
Administration:i.p.; twice weekly
-
Result:Caused significant tumor growth delay over 4 weeks.
Induced statistically significant differences in tumor volume relative to controls at multiple time points.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
-
Immobilized huHER3-Fc can bind MP-RM-1. The EC50 for this effect is 19.07 ng/mL.
Chemical Information
-
Appearance Liquid
-
Masse moléculaire 147.86 kDa
-
Color Colorless to off-white
-
SMILES
N/A
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MP-RM-1 Related Classifications
HY-P991243 Related Classifications
Powered by Bioz